
Objectives: Functional cure, defined by hepatitis B surface antigen loss, is the preferred therapeutic endpoint in chronic hepatitis B (CHB). The pan-immune-inflammation value (PIV) is an inflammation-based index derived from routine complete blood count parameters. This study investigated the association between PIV and functional cure in patients with CHB receiving nucleos(t)ide analogue (NA) therapy. Materials and Methods: This retrospective case-control study included 48 patients who achieved functional cure during NA therapy and 150 patients without functional cure as controls. PIV was evaluated at baseline and month-12. Receiver operating characteristic (ROC) analysis assessed the discriminatory performance of month-12 PIV, and multivariable logistic regression was used to identify factors independently associated with functional cure. Results: Baseline PIV was comparable between groups, whereas month-12 PIV was significantly lower in the functional cure group (p=0.007). The area under the ROC curve for month-12 PIV was 0.629 [95% confidence interval (CI), 0.535-0.720]. A cut-off value of 148.4 provided 47.9% sensitivity and 73.9% specificity. After adjustment for age, hepatitis B e antigen status, baseline hepatitis B virus-DNA level, and fibrosis score, month-12 PIV≤148.4 remained independently associated with functional cure [adjusted odds ratio (OR), 2.66; 95% CI, 1.29-5.47; p=0.008]. Older age was also independently associated with functional cure (adjusted OR per year, 1.05; 95% CI, 1.02-1.08; p=0.003). Conclusion: Lower month-12 PIV was independently associated with functional cure during NA therapy. Although its discriminatory ability was modest, PIV may provide a simple and inexpensive marker that could complement clinical and virological factors in the assessment of functional cure.